Boehringer Ingelheim, a global leader in animal health, is proud to announce that its Aservo EquiHaler received a 2021 Pharmapack Health Product Award in the newly established animal health category. The Health Product Awards also include patient-centric design and eco design categories. In 2020, the product received a Red Dot Award for outstanding product design.
Aservo EquiHaler is an inhalant therapy licensed for use in horses with severe equine asthma.
Launched in 1997, the Pharmapack Awards celebrate the latest innovations in pharma packaging and drug delivery devices within the drugs, medical devices, health products and veterinary drugs sectors. The awards recognise innovations that have improved drug efficacy, user safety or reduced the environmental impact. The jury comprises independent pharmacists, physicians and experts in patient-centric and sustainable packaging.
“This award is a fantastic acknowledgement of our purpose and vision – to improve the health of animals and humans. This innovative product is a result of the close collaboration between our animal and human health businesses, and so we are incredibly proud to see that it has received recognition by these prestigious awards,” comments Marc Laemmer, head of equine, Boehringer Ingelheim Animal Health UK and Ireland.
“What makes our Aservo EquiHaler stand out is the ergonomic handle and dosing lever for ease of use handling and the nostril adaptor that fits gently inside the horse’s nostril, allowing for easy inhalation of the medicated mist,” explains Martin Folger, principal fellow expert and risk management, global innovation, Boehringer Ingelheim. “We submitted this product because it is an industry first in equine medicine; until now, there was no approved inhalant therapy licensed for use in horses with severe equine asthma.”
Phillipe Arnaud, the chair of the Health Product Awards jury, comments: “After much discussion we decided to award a special prize for Animal Health to the Aservo EquiHaler from Boehringer Ingelheim; the jury was impressed by the innovative nature of the device. We look forward to seeing user feedback and case studies for this product.”
